RU2010102994A - Новые производные 1,2,3-триазола, полезные в качестве модуляторов никотиновых ацетилхолиновых рецепторов - Google Patents
Новые производные 1,2,3-триазола, полезные в качестве модуляторов никотиновых ацетилхолиновых рецепторов Download PDFInfo
- Publication number
- RU2010102994A RU2010102994A RU2010102994/04A RU2010102994A RU2010102994A RU 2010102994 A RU2010102994 A RU 2010102994A RU 2010102994/04 A RU2010102994/04 A RU 2010102994/04A RU 2010102994 A RU2010102994 A RU 2010102994A RU 2010102994 A RU2010102994 A RU 2010102994A
- Authority
- RU
- Russia
- Prior art keywords
- triazol
- ylamine
- trifluoromethylphenyl
- methoxyphenyl
- amino
- Prior art date
Links
- 150000000177 1,2,3-triazoles Chemical class 0.000 title claims 9
- 108010009685 Cholinergic Receptors Proteins 0.000 title 1
- 102000034337 acetylcholine receptors Human genes 0.000 title 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Chemical compound CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims abstract 13
- 239000000203 mixture Substances 0.000 claims abstract 11
- -1 hydroxy, amino Chemical group 0.000 claims abstract 10
- 125000000217 alkyl group Chemical group 0.000 claims abstract 8
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 8
- 239000001257 hydrogen Substances 0.000 claims abstract 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract 4
- 125000003545 alkoxy group Chemical group 0.000 claims abstract 4
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims abstract 4
- 125000003118 aryl group Chemical group 0.000 claims abstract 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract 4
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract 4
- 150000002431 hydrogen Chemical group 0.000 claims abstract 4
- 125000001715 oxadiazolyl group Chemical group 0.000 claims abstract 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract 4
- 125000001424 substituent group Chemical group 0.000 claims abstract 4
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims abstract 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract 4
- 125000000842 isoxazolyl group Chemical group 0.000 claims abstract 3
- 229910052736 halogen Inorganic materials 0.000 claims abstract 2
- 125000001475 halogen functional group Chemical group 0.000 claims abstract 2
- 150000002367 halogens Chemical class 0.000 claims abstract 2
- 208000002193 Pain Diseases 0.000 claims 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 208000035475 disorder Diseases 0.000 claims 5
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 claims 3
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 claims 3
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims 3
- 206010048010 Withdrawal syndrome Diseases 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000004296 neuralgia Diseases 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 2
- 206010010904 Convulsion Diseases 0.000 claims 2
- 206010012735 Diarrhoea Diseases 0.000 claims 2
- 208000026097 Factitious disease Diseases 0.000 claims 2
- 206010020651 Hyperkinesia Diseases 0.000 claims 2
- 208000000269 Hyperkinesis Diseases 0.000 claims 2
- 241001465754 Metazoa Species 0.000 claims 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 2
- 206010043118 Tardive Dyskinesia Diseases 0.000 claims 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims 2
- 206010015037 epilepsy Diseases 0.000 claims 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims 2
- 208000021722 neuropathic pain Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 claims 1
- BVSRMHRPTLJGNR-UHFFFAOYSA-N 2-[5-amino-1-(2,4-dichlorophenyl)triazol-4-yl]-4-chlorophenol Chemical compound NC1=C(C=2C(=CC=C(Cl)C=2)O)N=NN1C1=CC=C(Cl)C=C1Cl BVSRMHRPTLJGNR-UHFFFAOYSA-N 0.000 claims 1
- HJRWKGXLCYRXAS-UHFFFAOYSA-N 2-[5-amino-1-[2-chloro-4-(trifluoromethyl)phenyl]triazol-4-yl]-4-chlorophenol Chemical compound NC1=C(C=2C(=CC=C(Cl)C=2)O)N=NN1C1=CC=C(C(F)(F)F)C=C1Cl HJRWKGXLCYRXAS-UHFFFAOYSA-N 0.000 claims 1
- KZRHIVZDKQVNPN-UHFFFAOYSA-N 3-(2,4-dichloro-6-iodophenyl)-5-(4-methoxyphenyl)triazol-4-amine Chemical compound C1=CC(OC)=CC=C1C1=C(N)N(C=2C(=CC(Cl)=CC=2Cl)I)N=N1 KZRHIVZDKQVNPN-UHFFFAOYSA-N 0.000 claims 1
- YLZARLJSOWWBNL-UHFFFAOYSA-N 3-(2,4-dichlorophenyl)-5-(4-methoxyphenyl)triazol-4-amine Chemical compound C1=CC(OC)=CC=C1C1=C(N)N(C=2C(=CC(Cl)=CC=2)Cl)N=N1 YLZARLJSOWWBNL-UHFFFAOYSA-N 0.000 claims 1
- PEVDEGICNXHSSE-UHFFFAOYSA-N 3-(2-chloro-4-fluorophenyl)-5-(4-methoxyphenyl)triazol-4-amine Chemical compound C1=CC(OC)=CC=C1C1=C(N)N(C=2C(=CC(F)=CC=2)Cl)N=N1 PEVDEGICNXHSSE-UHFFFAOYSA-N 0.000 claims 1
- CJVBYZFANMMHHM-UHFFFAOYSA-N 3-[2-chloro-4-(trifluoromethyl)phenyl]-5-(4-methoxyphenyl)triazol-4-amine Chemical compound C1=CC(OC)=CC=C1C1=C(N)N(C=2C(=CC(=CC=2)C(F)(F)F)Cl)N=N1 CJVBYZFANMMHHM-UHFFFAOYSA-N 0.000 claims 1
- UUDQBGQGDILMHA-UHFFFAOYSA-N 3-[2-fluoro-4-(trifluoromethyl)phenyl]-5-(4-methoxyphenyl)triazol-4-amine Chemical compound C1=CC(OC)=CC=C1C1=C(N)N(C=2C(=CC(=CC=2)C(F)(F)F)F)N=N1 UUDQBGQGDILMHA-UHFFFAOYSA-N 0.000 claims 1
- LAYHRUYVNMGPET-UHFFFAOYSA-N 3-[2-fluoro-4-(trifluoromethyl)phenyl]-5-[4-(trifluoromethoxy)phenyl]triazol-4-amine Chemical compound NC1=C(C=2C=CC(OC(F)(F)F)=CC=2)N=NN1C1=CC=C(C(F)(F)F)C=C1F LAYHRUYVNMGPET-UHFFFAOYSA-N 0.000 claims 1
- YQQSSRXWYNOVBN-UHFFFAOYSA-N 4-[5-amino-1-(2,4-dichlorophenyl)triazol-4-yl]benzonitrile Chemical compound NC1=C(C=2C=CC(=CC=2)C#N)N=NN1C1=CC=C(Cl)C=C1Cl YQQSSRXWYNOVBN-UHFFFAOYSA-N 0.000 claims 1
- NPKRWBUJWKXGHT-UHFFFAOYSA-N 4-[5-amino-1-[2-chloro-4-(trifluoromethyl)phenyl]triazol-4-yl]phenol Chemical compound NC1=C(C=2C=CC(O)=CC=2)N=NN1C1=CC=C(C(F)(F)F)C=C1Cl NPKRWBUJWKXGHT-UHFFFAOYSA-N 0.000 claims 1
- RITFOWIQAQDPRO-UHFFFAOYSA-N 4-[5-amino-1-[2-fluoro-4-(trifluoromethyl)phenyl]triazol-4-yl]phenol Chemical compound NC1=C(C=2C=CC(O)=CC=2)N=NN1C1=CC=C(C(F)(F)F)C=C1F RITFOWIQAQDPRO-UHFFFAOYSA-N 0.000 claims 1
- HWAWIIPRNMFJMI-UHFFFAOYSA-N 4-[5-amino-4-[2-fluoro-4-(trifluoromethyl)phenyl]triazol-1-yl]benzenesulfonamide Chemical compound NC1=C(C=2C(=CC(=CC=2)C(F)(F)F)F)N=NN1C1=CC=C(S(N)(=O)=O)C=C1 HWAWIIPRNMFJMI-UHFFFAOYSA-N 0.000 claims 1
- HELKOFBFKICWNT-UHFFFAOYSA-N 4-[5-amino-4-[2-fluoro-4-(trifluoromethyl)phenyl]triazol-1-yl]phenol Chemical compound NC1=C(C=2C(=CC(=CC=2)C(F)(F)F)F)N=NN1C1=CC=C(O)C=C1 HELKOFBFKICWNT-UHFFFAOYSA-N 0.000 claims 1
- ZMRVSZFBDDJUMQ-UHFFFAOYSA-N 5-(2,4-dichlorophenyl)-3-(4-methoxyphenyl)triazol-4-amine Chemical compound C1=CC(OC)=CC=C1N1C(N)=C(C=2C(=CC(Cl)=CC=2)Cl)N=N1 ZMRVSZFBDDJUMQ-UHFFFAOYSA-N 0.000 claims 1
- XWFJEDOALHUHHM-UHFFFAOYSA-N 5-(2,4-difluorophenyl)-3-(4-methoxyphenyl)triazol-4-amine Chemical compound C1=CC(OC)=CC=C1N1C(N)=C(C=2C(=CC(F)=CC=2)F)N=N1 XWFJEDOALHUHHM-UHFFFAOYSA-N 0.000 claims 1
- ZDKRGWXNZRXQJP-UHFFFAOYSA-N 5-(2-chloro-4-fluorophenyl)-3-(4-methoxyphenyl)triazol-4-amine Chemical compound C1=CC(OC)=CC=C1N1C(N)=C(C=2C(=CC(F)=CC=2)Cl)N=N1 ZDKRGWXNZRXQJP-UHFFFAOYSA-N 0.000 claims 1
- FIYUJUMRDKTMKE-UHFFFAOYSA-N 5-(3,4-dichlorophenyl)-3-(4-methoxyphenyl)triazol-4-amine Chemical compound C1=CC(OC)=CC=C1N1C(N)=C(C=2C=C(Cl)C(Cl)=CC=2)N=N1 FIYUJUMRDKTMKE-UHFFFAOYSA-N 0.000 claims 1
- MSJMTNCXWPPVAT-UHFFFAOYSA-N 5-(4-aminophenyl)-3-[2-fluoro-4-(trifluoromethyl)phenyl]triazol-4-amine Chemical compound NC1=C(C=2C=CC(N)=CC=2)N=NN1C1=CC=C(C(F)(F)F)C=C1F MSJMTNCXWPPVAT-UHFFFAOYSA-N 0.000 claims 1
- NAXPHDYTHWICLV-UHFFFAOYSA-N 5-(4-chloro-2-fluorophenyl)-3-(4-methoxyphenyl)triazol-4-amine Chemical compound C1=CC(OC)=CC=C1N1C(N)=C(C=2C(=CC(Cl)=CC=2)F)N=N1 NAXPHDYTHWICLV-UHFFFAOYSA-N 0.000 claims 1
- JWXNCOWZOAWVOO-UHFFFAOYSA-N 5-(4-chlorophenyl)-3-[2-fluoro-4-(trifluoromethyl)phenyl]triazol-4-amine Chemical compound NC1=C(C=2C=CC(Cl)=CC=2)N=NN1C1=CC=C(C(F)(F)F)C=C1F JWXNCOWZOAWVOO-UHFFFAOYSA-N 0.000 claims 1
- ZWAJMZFSHJRPTF-UHFFFAOYSA-N 5-(4-methoxyphenyl)-3-(5-methyl-1,2-oxazol-3-yl)triazol-4-amine Chemical compound C1=CC(OC)=CC=C1C1=C(N)N(C2=NOC(C)=C2)N=N1 ZWAJMZFSHJRPTF-UHFFFAOYSA-N 0.000 claims 1
- SJJAODBZRZXEGS-UHFFFAOYSA-N 5-(5-chloro-2-methoxyphenyl)-3-(2,4-dichlorophenyl)triazol-4-amine Chemical compound COC1=CC=C(Cl)C=C1C1=C(N)N(C=2C(=CC(Cl)=CC=2)Cl)N=N1 SJJAODBZRZXEGS-UHFFFAOYSA-N 0.000 claims 1
- SRQGIQKNDGUPDC-UHFFFAOYSA-N 5-(5-chloro-2-methoxyphenyl)-3-[2-chloro-4-(trifluoromethyl)phenyl]triazol-4-amine Chemical compound COC1=CC=C(Cl)C=C1C1=C(N)N(C=2C(=CC(=CC=2)C(F)(F)F)Cl)N=N1 SRQGIQKNDGUPDC-UHFFFAOYSA-N 0.000 claims 1
- KIFSHCNOJWCTCK-UHFFFAOYSA-N 5-[2-fluoro-4-(trifluoromethyl)phenyl]-3-(4-methoxyphenyl)triazol-4-amine Chemical compound C1=CC(OC)=CC=C1N1C(N)=C(C=2C(=CC(=CC=2)C(F)(F)F)F)N=N1 KIFSHCNOJWCTCK-UHFFFAOYSA-N 0.000 claims 1
- YYTRPIAXOVEEDQ-UHFFFAOYSA-N 5-[4-chloro-2-(trifluoromethyl)phenyl]-3-(4-methoxyphenyl)triazol-4-amine Chemical compound C1=CC(OC)=CC=C1N1C(N)=C(C=2C(=CC(Cl)=CC=2)C(F)(F)F)N=N1 YYTRPIAXOVEEDQ-UHFFFAOYSA-N 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- 208000002874 Acne Vulgaris Diseases 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 208000000103 Anorexia Nervosa Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 206010003805 Autism Diseases 0.000 claims 1
- 208000020706 Autistic disease Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 208000032841 Bulimia Diseases 0.000 claims 1
- 206010006550 Bulimia nervosa Diseases 0.000 claims 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- 208000010228 Erectile Dysfunction Diseases 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010020850 Hyperthyroidism Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 206010026749 Mania Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 206010028403 Mutism Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000004983 Phantom Limb Diseases 0.000 claims 1
- 206010056238 Phantom pain Diseases 0.000 claims 1
- 208000008348 Post-Concussion Syndrome Diseases 0.000 claims 1
- 208000005107 Premature Birth Diseases 0.000 claims 1
- 206010036590 Premature baby Diseases 0.000 claims 1
- 206010036618 Premenstrual syndrome Diseases 0.000 claims 1
- 206010052276 Pseudodementia Diseases 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 206010039966 Senile dementia Diseases 0.000 claims 1
- 208000000323 Tourette Syndrome Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 206010000496 acne Diseases 0.000 claims 1
- 208000005298 acute pain Diseases 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 229940049706 benzodiazepine Drugs 0.000 claims 1
- 150000001557 benzodiazepines Chemical class 0.000 claims 1
- 208000028683 bipolar I disease Diseases 0.000 claims 1
- 229960003920 cocaine Drugs 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 230000008602 contraction Effects 0.000 claims 1
- 230000036461 convulsion Effects 0.000 claims 1
- 229960002069 diamorphine Drugs 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 206010013932 dyslexia Diseases 0.000 claims 1
- 208000030172 endocrine system disease Diseases 0.000 claims 1
- 201000001881 impotence Diseases 0.000 claims 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 201000003723 learning disability Diseases 0.000 claims 1
- 230000029849 luteinization Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 206010027175 memory impairment Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 229960005181 morphine Drugs 0.000 claims 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims 1
- YEZGCZLZALVFGW-UHFFFAOYSA-N n-[4-[5-amino-1-[2-fluoro-4-(trifluoromethyl)phenyl]triazol-4-yl]phenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1C1=C(N)N(C=2C(=CC(=CC=2)C(F)(F)F)F)N=N1 YEZGCZLZALVFGW-UHFFFAOYSA-N 0.000 claims 1
- 201000003631 narcolepsy Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 208000019906 panic disease Diseases 0.000 claims 1
- 210000000578 peripheral nerve Anatomy 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 206010036596 premature ejaculation Diseases 0.000 claims 1
- 201000004700 rosacea Diseases 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 230000020341 sensory perception of pain Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 208000005057 thyrotoxicosis Diseases 0.000 claims 1
- 208000002271 trichotillomania Diseases 0.000 claims 1
- 125000001399 1,2,3-triazolyl group Chemical class N1N=NC(=C1)* 0.000 abstract 5
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Gynecology & Obstetrics (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Pregnancy & Childbirth (AREA)
- Psychology (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Nutrition Science (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200701134 | 2007-08-08 | ||
| DKPA200701134 | 2007-08-08 | ||
| US95508107P | 2007-08-10 | 2007-08-10 | |
| US60/955,081 | 2007-08-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2010102994A true RU2010102994A (ru) | 2011-09-20 |
Family
ID=39870242
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010102994/04A RU2010102994A (ru) | 2007-08-08 | 2008-08-06 | Новые производные 1,2,3-триазола, полезные в качестве модуляторов никотиновых ацетилхолиновых рецепторов |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8110588B2 (https=) |
| EP (1) | EP2185529A1 (https=) |
| JP (1) | JP2010535738A (https=) |
| KR (1) | KR20100046179A (https=) |
| CN (1) | CN101796034A (https=) |
| AU (1) | AU2008285644A1 (https=) |
| CA (1) | CA2695812A1 (https=) |
| MX (1) | MX2010001135A (https=) |
| NZ (1) | NZ582520A (https=) |
| RU (1) | RU2010102994A (https=) |
| WO (1) | WO2009019278A1 (https=) |
| ZA (1) | ZA201000127B (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009112459A1 (en) * | 2008-03-11 | 2009-09-17 | Neurosearch A/S | Novel 1,2,3-triazole derivatives useful as modulators of nicotinic acetylcholine receptors |
| JP2011530495A (ja) * | 2008-08-08 | 2011-12-22 | ノイロサーチ アクティーゼルスカブ | ニコチン性アセチルコリン受容体のモジュレーターとして有用な新規のジフェニル１，２，３−トリアゾール誘導体 |
| CA2735773A1 (en) * | 2008-09-02 | 2010-03-11 | Neurosearch A/S | Triazole derivatives and their use as nicotinic acetylcholine receptor modulators |
| TW201124406A (en) | 2009-10-07 | 2011-07-16 | Karobio Ab | Novel estrogen receptor ligands |
| KR20140041442A (ko) | 2011-02-03 | 2014-04-04 | 루핀 리미티드 | 알파 7 ｎａｃｈｒ의 조절자로 사용된 피롤 유도체 |
| EA024170B1 (ru) | 2011-02-23 | 2016-08-31 | Люпин Лимитед | ГЕТЕРОАРИЛЬНЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ nAChR АЛЬФА7 |
| EP2691368A1 (en) | 2011-03-31 | 2014-02-05 | Lupin Limited | Pyrrole derivatives as nicotinic acetylcholine receptor modulators for use in the treatment of neurodegenerative disorders such as alzheimer's and parkinson's disease |
| FR2974365B1 (fr) * | 2011-04-20 | 2017-08-25 | Centre Nat De La Rech Scient (C N R S) | 1,2,3-triazoles 1,4-disubstituees, leurs procedes de preparation et leurs utilisations diagnostiques et therapeutiques |
| EP2729455B1 (en) | 2011-07-05 | 2016-09-14 | Lupin Limited | Biaryl derivatives as nachr modulators |
| GB201113538D0 (en) | 2011-08-04 | 2011-09-21 | Karobio Ab | Novel estrogen receptor ligands |
| EP2822946A1 (en) | 2012-03-06 | 2015-01-14 | Lupin Limited | Thiazole derivatives as alpha 7 nachr modulators |
| US20150299178A1 (en) | 2012-11-12 | 2015-10-22 | Lupin Limited | Thiazole Derivatives as Alpha 7 NACHR Modulators |
| US9617211B2 (en) | 2013-01-16 | 2017-04-11 | Lupin Limited | Pyrrole derivatives as alpha 7 nAChR modulators |
| AU2014229300A1 (en) | 2013-03-13 | 2015-06-11 | Lupin Limited | Pyrrole derivatives as alpha 7 nAChR modulators |
| TW201446243A (zh) | 2013-06-03 | 2014-12-16 | Lupin Ltd | 4-(5-(4-氯苯基)-2-(2-環丙基乙醯基)-1,4-二甲基-1氫-吡咯-3-基)苯磺醯胺作為α7尼古丁乙醯膽鹼受體調節劑 |
| AU2014282886A1 (en) | 2013-06-17 | 2015-12-17 | Lupin Limited | Pyrrole derivatives as alpha 7 nAChR modulators |
| US20210163425A1 (en) | 2017-12-20 | 2021-06-03 | Gyeonggido Business & Science Accelerator | Triazole derivative and use thereof |
| CN113045507B (zh) * | 2021-03-04 | 2022-10-25 | 中山大学南方学院 | 一种3,4-二羟基苯甲酸甲酯衍生物及其制备方法与应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1242216B (de) | 1963-12-27 | 1967-06-15 | Union Carbide Corp | Verfahren zur Herstellung von Inaminsalzen |
| DE60222698T2 (de) * | 2001-12-18 | 2008-06-19 | Merck & Co., Inc. | Heteroarylsubstituierte triazolmodulatoren des metabotropen glutamatarezeptors 5 |
| AU2003230829B8 (en) | 2002-04-26 | 2008-12-11 | Eli Lilly And Company | Triazole derivatives as tachykinin receptor antagonists |
| RU2006142896A (ru) | 2004-05-06 | 2008-06-20 | Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния (Us) | Замещенные енаминоны, их производные и их применение |
| WO2006071184A1 (en) | 2004-12-28 | 2006-07-06 | Astrazeneca Ab | Aryl sulphonamide modulators |
| WO2009112459A1 (en) | 2008-03-11 | 2009-09-17 | Neurosearch A/S | Novel 1,2,3-triazole derivatives useful as modulators of nicotinic acetylcholine receptors |
| JP2011530495A (ja) | 2008-08-08 | 2011-12-22 | ノイロサーチ アクティーゼルスカブ | ニコチン性アセチルコリン受容体のモジュレーターとして有用な新規のジフェニル１，２，３−トリアゾール誘導体 |
-
2008
- 2008-08-06 WO PCT/EP2008/060307 patent/WO2009019278A1/en not_active Ceased
- 2008-08-06 CN CN200880102108A patent/CN101796034A/zh active Pending
- 2008-08-06 JP JP2010519457A patent/JP2010535738A/ja not_active Abandoned
- 2008-08-06 CA CA2695812A patent/CA2695812A1/en not_active Abandoned
- 2008-08-06 MX MX2010001135A patent/MX2010001135A/es not_active Application Discontinuation
- 2008-08-06 NZ NZ582520A patent/NZ582520A/en not_active IP Right Cessation
- 2008-08-06 KR KR1020107002808A patent/KR20100046179A/ko not_active Withdrawn
- 2008-08-06 AU AU2008285644A patent/AU2008285644A1/en not_active Abandoned
- 2008-08-06 US US12/672,252 patent/US8110588B2/en not_active Expired - Fee Related
- 2008-08-06 EP EP08786915A patent/EP2185529A1/en not_active Withdrawn
- 2008-08-06 RU RU2010102994/04A patent/RU2010102994A/ru not_active Application Discontinuation
-
2010
- 2010-01-07 ZA ZA2010/00127A patent/ZA201000127B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2010001135A (es) | 2010-03-09 |
| AU2008285644A1 (en) | 2009-02-12 |
| KR20100046179A (ko) | 2010-05-06 |
| ZA201000127B (en) | 2011-03-30 |
| US8110588B2 (en) | 2012-02-07 |
| WO2009019278A1 (en) | 2009-02-12 |
| US20100222398A1 (en) | 2010-09-02 |
| EP2185529A1 (en) | 2010-05-19 |
| CA2695812A1 (en) | 2009-02-12 |
| CN101796034A (zh) | 2010-08-04 |
| JP2010535738A (ja) | 2010-11-25 |
| NZ582520A (en) | 2011-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2010102994A (ru) | Новые производные 1,2,3-триазола, полезные в качестве модуляторов никотиновых ацетилхолиновых рецепторов | |
| JP2010535738A5 (https=) | ||
| JP4630662B2 (ja) | Ｉ．Ａ．慢性関節リウマチの治療においてｐ３８キナーゼ阻害剤として使用される縮合ヘテロアリール誘導体 | |
| RU2649976C2 (ru) | Способ получения бензоксазепиновых соединений | |
| TW200911232A (en) | Novel therapeutic compounds | |
| JP6605020B2 (ja) | Ｎｒ２ｂ受容体阻害剤としてのトリアゾール | |
| US20050096327A1 (en) | Novel norepinephrine reuptake inhibitors for the treatment of central nervous system disorders | |
| EP2846794A1 (en) | BICYCLIC SULFONE COMPOUNDS FOR INHIBITION OF RORy ACTIVITY AND THE TREATMENT OF DISEASE | |
| EA005316B1 (ru) | Арилконденсированные азаполициклические соединения | |
| WO2008055932A1 (en) | 1,2,4-triazole derivatives as sigma receptor inhibitors | |
| JP2005511532A (ja) | ５’−カルバモイル−１，１−ビフェニル−４−カルボキサミド誘導体及びそのｐ３８キナーゼ阻害薬としての使用 | |
| CA2667545A1 (en) | Oxadiazole and thiadiazole compounds and their use as nicotinic acetylcholine receptor modulators | |
| JP2009538866A5 (https=) | ||
| JP2009538867A5 (https=) | ||
| HUE033134T2 (en) | Phenyl-3-aza-bicyclo[3.1.0]hex-3-yl-methanones and the use thereof as medicament | |
| RU2010135035A (ru) | Новые триарильные производные, полезные в качестве модуляторов никотиновых ацетилхолиновых рецепторов | |
| WO2008142550A2 (en) | Spirocyclic derivatives | |
| WO2015167968A1 (en) | Optically active pde10 inhibitor | |
| JP4146641B2 (ja) | ３−アミノ−１−フェニル−１ｈ−［１，２，４］トリアゾールの新規な分岐状置換アミノ誘導体、それらの製造法およびそれらを含む医薬組成物 | |
| JP2007520472A (ja) | ブラジキニン拮抗物質又は逆作用物質としてのアルファ−ヒドロキシアミド | |
| JP2020524660A (ja) | Ｒｏｒ−ガンマモジュレーターとして有用な２，３−ジヒドロイソインドール−１−カルボキサミド | |
| CN102123992A (zh) | 用作烟碱型乙酰胆碱受体调节剂的新颖的二苯基1，2，3-三唑衍生物 | |
| Kinena et al. | Azole‐based non‐peptidomimetic plasmepsin inhibitors | |
| CA2673601A1 (en) | Heterocyclyl-substituted-ethylamino-phenyl derivatives, their preparation and use as medicaments | |
| JP2008502650A5 (https=) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20120918 |